Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes soul trial results NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Read the full trial results at NEJM.org (link in bio). , , #ACC25 #Cardiology #ClinicalTrials #NEJM orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes soul trial results NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Read the full trial results at NEJM.org (link in bio). , , #ACC25 #Cardiology #ClinicalTrials #NEJM ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes soul trial results NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Read the full trial results at NEJM.org (link in bio). , , #ACC25 #Cardiology #ClinicalTrials #NEJM, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes soul trial results NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Read the full trial results at NEJM.org (link in bio). , , #ACC25 #Cardiology #ClinicalTrials #NEJM in your area.
Full article: Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients
20.70
A secondary analysis of the SOUL trial showed that oral semaglutide, like the injected form, improves outcomes related to heart failure in high-risk patients with diabetes
23.99
Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results
26.78
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design
20.29
Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
28.75
Novo Nordisk's Semaglutide lowers MACE risk in SOUL trial
25.46
Oral Semaglutide Cuts Cardiovascular Risk by 14% in SOUL Trial
23.15
